Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bazedoxifene Acetate

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Bazedoxifene Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Postmenopausal osteoporosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective estrogen receptor modulators
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bazedoxifene Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bazedoxifene Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Affect of Duavive on Mood & Anxiety Symptoms

    NCT04478305 · start 2024-07-03

    Registered record
    Registry ID
    NCT04478305
    Conditions
    Menopause; Depression, Anxiety; Sleep; Menopause Related Conditions
    Interventions
    Duavive 0.45Mg-20Mg Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-07-03
    Completion
    2025-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopause; Depression, Anxiety; Sleep; Menopause Related Conditions
    InterventionDuavive 0.45Mg-20Mg Tablet
    PhasePhase 1
    Registry statusRecruiting

  • Effects of Novel Estrogens on Glucose and Lipids in Postmenopausal Prediabetic Women Veterans

    NCT05073237 · start 2024-04-08

    Registered record
    Registry ID
    NCT05073237
    Conditions
    Menopause; Prediabetes; Obesity
    Interventions
    Placebo; conjugated estrogens/bazedoxifene (CE/BZA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2024-04-08
    Completion
    2024-04-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopause; Prediabetes; Obesity
    InterventionPlacebo; conjugated estrogens/bazedoxifene (CE/BZA)
    PhasePhase 2
    Registry statusWithdrawn

  • Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee

    NCT05059626 · start 2023-12-01

    Registered record
    Registry ID
    NCT05059626
    Conditions
    Endometriosis
    Interventions
    simvastatin 10mg; Bazedoxifene 20/Estrogens,Con 0.45Mg Tb
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Enrolling by invitation
    Start
    2023-12-01
    Completion
    2026-12-31
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    Interventionsimvastatin 10mg; Bazedoxifene 20/Estrogens,Con 0.45Mg Tb
    PhasePhase 4
    Registry statusEnrolling by invitation

  • Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma

    NCT04812808 · start 2022-02-01

    Registered record
    Registry ID
    NCT04812808
    Conditions
    Pancreas Cancer
    Interventions
    Bazedoxifene 20 mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-02-01
    Completion
    2024-05-31
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreas Cancer
    InterventionBazedoxifene 20 mg
    PhaseNot applicable
    Registry statusUnknown

  • Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens

    NCT04821141 · start 2021-12-14

    Registered record
    Registry ID
    NCT04821141
    Conditions
    Risk Reduction; Breast Cancer
    Interventions
    Bazedoxifene and Conjugated Estrogens
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-12-14
    Completion
    2027-07-31
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRisk Reduction; Breast Cancer
    InterventionBazedoxifene and Conjugated Estrogens
    PhasePhase 2
    Registry statusActive not recruiting

  • Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers

    NCT04821375 · start 2021-12-02

    Registered record
    Registry ID
    NCT04821375
    Conditions
    Increased Risk for Development of Breast Cancer
    Interventions
    bazedoxifene plus conjugated estrogens
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2021-12-02
    Completion
    2024-12-31
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIncreased Risk for Development of Breast Cancer
    Interventionbazedoxifene plus conjugated estrogens
    PhaseEarly phase 1
    Registry statusCompleted

  • Advancing Postmenopausal Preventive Therapy

    NCT04103476 · start 2021-04-13

    Registered record
    Registry ID
    NCT04103476
    Conditions
    Atherosclerosis; Cognitive Decline
    Interventions
    Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-04-13
    Completion
    2026-12-31
    Enrolment
    385

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis; Cognitive Decline
    InterventionOral bazedoxifene 20 mg / conjugated estrogens 0.45 mg; Placebo
    PhasePhase 2
    Registry statusActive not recruiting

  • Post-fracture Medication and Mortality

    NCT05366621 · start 2020-11-01

    Registered record
    Registry ID
    NCT05366621
    Conditions
    Osteoporosis; Osteoporosis Fracture; Drug Therapy; Mortality; Adherence, Medication
    Interventions
    Anti-osteoporosis medications
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-11-01
    Completion
    2021-10-31
    Enrolment
    216,155

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis; Osteoporosis Fracture; Drug Therapy; Mortality +1 more
    InterventionAnti-osteoporosis medications
    PhaseNot recorded
    Registry statusCompleted

  • Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms

    NCT04379024 · start 2020-06-01

    Registered record
    Registry ID
    NCT04379024
    Conditions
    Focus of Study is Healthy Women at Risk for Breast Cancer
    Interventions
    DUAVEE 0.45Mg-20Mg Tablet
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2020-06-01
    Completion
    2021-07-31
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFocus of Study is Healthy Women at Risk for Breast Cancer
    InterventionDUAVEE 0.45Mg-20Mg Tablet
    PhaseEarly phase 1
    Registry statusTerminated

  • Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis

    NCT04002934 · start 2019-09-10

    Registered record
    Registry ID
    NCT04002934
    Conditions
    Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting
    Interventions
    Bazedoxifene Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-09-10
    Completion
    2025-05-20
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting
    InterventionBazedoxifene Acetate
    PhasePhase 2
    Registry statusCompleted

  • Can we Use Estrogen-containing Therapy to Improve Pain in Women After Menopause With Hand Osteoarthritis?

    NCT04036929 · start 2019-05-09

    Registered record
    Registry ID
    NCT04036929
    Conditions
    Hand Osteoarthritis
    Interventions
    Estrogen-bazedoxifene; Placebo oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-05-09
    Completion
    2021-12-10
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHand Osteoarthritis
    InterventionEstrogen-bazedoxifene; Placebo oral tablet
    PhaseNot applicable
    Registry statusCompleted

  • Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause"

    NCT03740009 · start 2019-01-02

    Registered record
    Registry ID
    NCT03740009
    Conditions
    Perimenopausal Disorder; Depression
    Interventions
    Bazedoxifene/Conjugated Estrogen
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-01-02
    Completion
    2021-05-17
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerimenopausal Disorder; Depression
    InterventionBazedoxifene/Conjugated Estrogen
    PhasePhase 4
    Registry statusCompleted

  • A Clinical Trial to Evaluate the Safety and Pharmacokinetic

    NCT03475719 · start 2018-01-11

    Registered record
    Registry ID
    NCT03475719
    Conditions
    Osteoporosis, Postmenopausal
    Interventions
    HUG186-B and HUG186-D; HUG186
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2018-01-11
    Completion
    2018-04-30
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis, Postmenopausal
    InterventionHUG186-B and HUG186-D; HUG186
    PhasePhase 1
    Registry statusUnknown

  • HDDO-1614 Bio Equivalence Study

    NCT03382314 · start 2017-10-16

    Registered record
    Registry ID
    NCT03382314
    Conditions
    Osteoporosis
    Interventions
    HDDO-1614; Bazedoxifene / Cholecalciferol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-10-16
    Completion
    2018-01-05
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis
    InterventionHDDO-1614; Bazedoxifene / Cholecalciferol
    PhasePhase 1
    Registry statusCompleted

  • AK-R215 Pharmacokinetic Study Phase I

    NCT03321318 · start 2017-07-13

    Registered record
    Registry ID
    NCT03321318
    Conditions
    Healthy
    Interventions
    AK-R215; Bazedoxifene 20 mg; Cholecalciferol 800IU
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2017-07-13
    Completion
    2018-01-12
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAK-R215; Bazedoxifene 20 mg; Cholecalciferol 800IU
    PhasePhase 1
    Registry statusUnknown